See more : Jubilee Gold Exploration Ltd. (JBULF) Income Statement Analysis – Financial Results
Complete financial analysis of Myovant Sciences Ltd. (MYOV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Myovant Sciences Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Shimizu Corporation (1803.T) Income Statement Analysis – Financial Results
- Plastika Kritis S.A. (PLAKR.AT) Income Statement Analysis – Financial Results
- Zentalis Pharmaceuticals, Inc. (ZNTL) Income Statement Analysis – Financial Results
- Pendal Group Limited (PDL.AX) Income Statement Analysis – Financial Results
- TechPrecision Corporation (TPCS) Income Statement Analysis – Financial Results
Myovant Sciences Ltd. (MYOV)
About Myovant Sciences Ltd.
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 230.97M | 59.32M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 51.55M | 1.97M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 179.42M | 57.35M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 77.68% | 96.69% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 107.40M | 136.71M | 192.56M | 222.61M | 116.83M | 43.50M |
| General & Administrative | 0.00 | 0.00 | 82.33M | 42.22M | 24.23M | 12.36M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 259.36M | 181.42M | 82.33M | 42.22M | 24.23M | 12.36M |
| Other Expenses | 40.04M | 1.66M | 1.62M | -309.00K | 67.00K | -139.00K |
| Operating Expenses | 366.77M | 318.14M | 274.89M | 264.83M | 141.06M | 55.86M |
| Cost & Expenses | 418.32M | 320.10M | 274.89M | 264.83M | 141.06M | 55.86M |
| Interest Income | 384.00K | 211.00K | 2.55M | 881.00K | 0.00 | 0.00 |
| Interest Expense | 13.97M | 10.40M | 12.66M | 8.82M | 2.05M | 0.00 |
| Depreciation & Amortization | 3.46M | 2.69M | 1.77M | 438.00K | 243.00K | 61.00K |
| EBITDA | -183.89M | -258.09M | -273.80M | -255.88M | -140.75M | 0.00 |
| EBITDA Ratio | -79.62% | -435.11% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -187.35M | -260.78M | -270.71M | -264.83M | -141.06M | -55.86M |
| Operating Income Ratio | -81.11% | -439.64% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.59M | 5.99M | -17.51M | -8.25M | -1.98M | -27.66M |
| Income Before Tax | -200.93M | -254.80M | -288.23M | -273.08M | -143.04M | -83.51M |
| Income Before Tax Ratio | -86.99% | -429.55% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 5.05M | 336.00K | 761.00K | 476.00K | 213.00K | -74.00K |
| Net Income | -205.98M | -255.13M | -288.99M | -273.55M | -143.26M | -83.44M |
| Net Income Ratio | -89.18% | -430.12% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.22 | -2.83 | -3.37 | -4.09 | -2.41 | -1.70 |
| EPS Diluted | -2.22 | -2.83 | -3.37 | -4.09 | -2.41 | -1.70 |
| Weighted Avg Shares Out | 92.97M | 90.04M | 85.84M | 66.91M | 59.52M | 49.18M |
| Weighted Avg Shares Out (Dil) | 92.97M | 90.04M | 85.84M | 66.91M | 59.52M | 49.18M |
Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the Virtual 2021 Annual Meeting of the American Urological Association
Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference
Here's Why Myovant Sciences Stock Is Falling Today
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q1 2021 Results - Earnings Call Transcript
Myovant Sciences (MYOV) Reports Q1 Loss, Misses Revenue Estimates
Recap: Myovant Sciences Q1 Earnings
Europe OK's Myovant's Relugolix Combo Therapy For Uterine Fibroids
Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids
3 Big Drugmakers Likely to be in Focus in Second Half of 2021
3 Biotech Stocks Ready for Big Breakthroughs Like Biogen
Source: https://incomestatements.info
Category: Stock Reports